

Supplementary Document III – Distribution for the generation of synthetic dataset

<i>Parameter name</i>	<i>Distribution type</i>			<i>Ref</i>
Age (years)	Normal	$\mu = 60$	$\sigma = 10$	[1–5]
PSA (ng/mL)	Beta	$\alpha = 4.17$	$\beta = 51.5$	[1–5]
BMI (kg/m ²)	Normal	$\mu = 28$	$\sigma = 3$	[3–5]
T-stage	Step	T1 = 66%	T2 = 34%	[1, 3–5]
neg. biopsy cores (N)	Normal	$\mu = 4.5$	$\sigma = 1.9$	[2]
pos. biopsy cores (N)	Half normal	Location = 1	Scale = 2.46	[2]
P. Gleason grade	Beta	4 = 14%	3 = 86%	[1, 3, 4]
S. Gleason grade	Step	4 = 19%	3 = 71%	[2]
ADT given	Step	no = 22%	yes = 78%	[6]
ADT length	Beta	$\alpha = 0.125$	$\beta = 1.25$	[1]
ASA score	Step	I/II = 18%	III/IV = 82%	[1, 3]
Nerve sparing	Step	no = 81%	yes = 19%	[4]
Abdominal surgery	Step	no = 90.3%	yes = 9.7%	[6]
HRQOL (%)	Beta	$\alpha = 1.5$	$\beta = 6$	[5]
Membranous urethra length (mm)	Normal	$\mu = 12$	$\sigma = 3$	[4]
Mean Trigone dose (Gy)	Normal	$\mu = 68$	$\sigma = 6$	[3]
V75 rectum (%)	Gamma	location = 1	scale = 4	[6]

Ref: reference; PSA: prostate specific antigen; BMI: body mass index; T-stage: Tumor stage; N neg.: number of negative; N pos.: number of positive; P.: Primary; S.: Secondary; ADT: androgen deprivation therapy; ASA: American Society of Anesthesiologists; PN: Pelvic nodes; HRQOL: sexual health-related quality of life; V75: percentage receiving at least 75 Gray; Gy = Gray

1. Warner A, Pickles T, Crook J, et al (2015) Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. *Cureus* 7:e276
2. Bjartell A, Bottai M, Persson J, et al (2016) Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. *Scandinavian Journal of Urology* 50:255–259
3. Schaafe W, van der Schaaf A, van Dijk LV, et al (2018) Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients. *PLoS One* 13:e0197757
4. Matsushita K, Kent MT, Vickers AJ, et al (2015) Preoperative predictive model of recovery of urinary continence after radical prostatectomy. *BJU Int* 116:577–583
5. Alemozaffar M, Regan MM, Cooperberg MR, et al (2011) Prediction of erectile function following treatment for prostate cancer. *JAMA* 306:1205–1214
6. Valdagni R, Kattan MW, Rancati T, et al (2012) Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. *Int J Radiat Oncol Biol Phys* 82:1957–1966